ReviewBest practice & research. Clinical rheumatology2022
Precision medicine in rheumatoid arthritis.
Review in Best practice & research. Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Mendelian randomization identifies multiple immune cell surface markers as potential causal contributors and drug targets in rheumatoid arthritis.The Journal of international medical research · 2026Pooled it
- Article
- Cellular miRNA-31 and miRNA-125b as predictors of remission and major disease improvement in patients with early rheumatoid arthritis.Scientific reports · 2026Article
- Immunometabolism in rheumatoid arthritis: mechanisms, biomarkers, and the path to precision medicine.Frontiers in immunology · 2026Review
- Precision medicine in rheumatoid arthritis: advances and clinical applications of multi-omics biomarkers.Frontiers in immunology · 2026Review
- Article
- Harnessing organoid technology to model autoimmune pathways in rheumatological and inflammatory disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Epigenetic modifications of immune cells in rheumatoid arthritis.Annals of medicine · 2025Review
- Targeted nanoliposomes for precision rheumatoid arthritis therapy: a review on mechanisms andDrug delivery · 2025Review
- Immunosenescence and organoids: pathophysiology and therapeutic opportunities.Immunity & ageing : I & A · 2025Review
- Synovial organoids: From fundamental construction to groundbreaking applications in arthritic disorders.Journal of orthopaedic translation · 2025Review
- [Immunoadsorption in rheumatic autoimmune diseases: an alternative treatment option : Retrospective insights on the clinical application from the Rhineland-Palatinate Rheumatology Center].Zeitschrift fur Rheumatologie · 2025Article
- Bone organoid construction and evolution.Journal of orthopaedic translation · 2025Review
- Article
- Regulation of neutrophil associated RNASET2 expression in rheumatoid arthritis.Scientific reports · 2024Article
- Review
- Synovial Tissue Insights into Heterogeneity of Rheumatoid Arthritis.Current rheumatology reports · 2024Review
- Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis.Frontiers in immunology · 2023Article
- Cartilage organoids for cartilage development and cartilage-associated disease modeling.Frontiers in cell and developmental biology · 2023Article
- 3D Cell Culture as Tools to Characterize Rheumatoid Arthritis Signaling and Development of New Treatments.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Rheumatoid arthritis is an autoimmune disease that causes significant morbidity. Application of cellular profiling techniques such as single-cell transcriptomics and spatial transcriptomics has uncovered novel pathogenic cell types in RA joint tissues and revealed marked heterogeneity in the cellular composition among RA patients. Together, these insights provide exciting opportunities to translate discoveries into precision medicine in RA. The present review aims to highlight novel insights into RA pathology and discuss key steps needed to translate these discoveries into actionable changes in clinical practice. We review the efforts to identify surrogate biomarkers that could be used to predict RA synovial tissue phenotypes and the corresponding responses to therapy. Finally, we discuss the opportunity to develop novel patient-derived organoid systems as a platform for therapeutic target validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.